AAREYDRUGS Stock Overview
Aarey Drugs & Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients, bulk drugs, intermediates, and specialty chemicals for various industrial applications in India.
Aarey Drugs & Pharmaceuticals Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||₹32.10|
|52 Week High||₹64.35|
|52 Week Low||₹28.25|
|1 Month Change||-9.83%|
|3 Month Change||-22.37%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-25.95%|
Recent News & Updates
Aarey Drugs & Pharmaceuticals Limited (NSE:AAREYDRUGS) Shares Fly 25% But Investors Aren't Buying For Growth
The Aarey Drugs & Pharmaceuticals Limited ( NSE:AAREYDRUGS ) share price has done very well over the last month...
|AAREYDRUGS||IN Pharmaceuticals||IN Market|
Return vs Industry: Insufficient data to determine how AAREYDRUGS performed against the Indian Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how AAREYDRUGS performed against the Indian Market.
|AAREYDRUGS Average Weekly Movement||7.2%|
|Pharmaceuticals Industry Average Movement||6.8%|
|Market Average Movement||6.9%|
|10% most volatile stocks in IN Market||9.9%|
|10% least volatile stocks in IN Market||4.5%|
Stable Share Price: AAREYDRUGS is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: AAREYDRUGS's weekly volatility (7%) has been stable over the past year.
About the Company
Aarey Drugs & Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients, bulk drugs, intermediates, and specialty chemicals for various industrial applications in India. The company provides mono methyl and die methyl urea, ortho para nitro anisole, 2 bromomethyl 1,3 dioxalane, uracile and active pharma ingredients, such as metformin HCL, mefenamic acid, and doxophylline. It also offers chemicals and solvents, which include aeromatics chemicals, chemical acids, chlor alkalies, glycols and glycol ethers, fiber intermediates, acetates and esters, and chlorinated solvents, as well as industrial alchols, ketones, amines, oleochemicals, intermediates, olefines, phosphates, fertilizers, monomers, and chemicals.
Aarey Drugs & Pharmaceuticals Fundamentals Summary
|AAREYDRUGS fundamental statistics|
Is AAREYDRUGS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AAREYDRUGS income statement (TTM)|
|Cost of Revenue||₹4.67b|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||2.58|
|Net Profit Margin||1.32%|
How did AAREYDRUGS perform over the long term?See historical performance and comparison
Is AAREYDRUGS undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for AAREYDRUGS?
Other financial metrics that can be useful for relative valuation.
|What is AAREYDRUGS's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does AAREYDRUGS's PE Ratio compare to its peers?
|AAREYDRUGS PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
537253 Sunil Healthcare
524396 Biofil Chemicals and Pharmaceuticals
506128 Parnax Lab
524506 Coral Laboratories
AAREYDRUGS Aarey Drugs & Pharmaceuticals
Price-To-Earnings vs Peers: AAREYDRUGS is good value based on its Price-To-Earnings Ratio (12.5x) compared to the peer average (38.5x).
Price to Earnings Ratio vs Industry
How does AAREYDRUGS's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?
Price-To-Earnings vs Industry: AAREYDRUGS is good value based on its Price-To-Earnings Ratio (12.5x) compared to the Indian Pharmaceuticals industry average (20.7x)
Price to Earnings Ratio vs Fair Ratio
What is AAREYDRUGS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||12.5x|
|Fair PE Ratio||n/a|
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate AAREYDRUGS's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of AAREYDRUGS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate AAREYDRUGS's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate AAREYDRUGS's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AAREYDRUGS's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Aarey Drugs & Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Aarey Drugs & Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Examine Aarey Drugs & Pharmaceuticals's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Aarey Drugs & Pharmaceuticals competitive advantages and company strategy can generally be found in its financial reports archived here.
How has Aarey Drugs & Pharmaceuticals performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AAREYDRUGS has high quality earnings.
Growing Profit Margin: AAREYDRUGS's current net profit margins (1.3%) are lower than last year (1.9%).
Past Earnings Growth Analysis
Earnings Trend: AAREYDRUGS's earnings have grown by 3.1% per year over the past 5 years.
Accelerating Growth: AAREYDRUGS's earnings growth over the past year (0.5%) is below its 5-year average (3.1% per year).
Earnings vs Industry: AAREYDRUGS earnings growth over the past year (0.5%) underperformed the Pharmaceuticals industry 9%.
Return on Equity
High ROE: AAREYDRUGS's Return on Equity (5.8%) is considered low.
Discover strong past performing companies
How is Aarey Drugs & Pharmaceuticals's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: AAREYDRUGS's short term assets (₹2.1B) exceed its short term liabilities (₹1.3B).
Long Term Liabilities: AAREYDRUGS's short term assets (₹2.1B) exceed its long term liabilities (₹14.6M).
Debt to Equity History and Analysis
Debt Level: AAREYDRUGS's net debt to equity ratio (12.3%) is considered satisfactory.
Reducing Debt: AAREYDRUGS's debt to equity ratio has reduced from 21.1% to 12.5% over the past 5 years.
Debt Coverage: AAREYDRUGS's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: AAREYDRUGS's interest payments on its debt are well covered by EBIT (6x coverage).
Discover healthy companies
What is Aarey Drugs & Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AAREYDRUGS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AAREYDRUGS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AAREYDRUGS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AAREYDRUGS's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: AAREYDRUGS is not paying a notable dividend for the Indian market.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as AAREYDRUGS has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mihir Ghatalia (38 yo)
Mr. Mihir Rajesh Ghatalia, B.E., serves as an Executive Director at Worth Investment & Trading Company Limited. He has been the Managing Director at Aarey Drugs & Pharmaceuticals Ltd. since December 29, 20...
CEO Compensation Analysis
Compensation vs Market: Mihir's total compensation ($USD13.76K) is below average for companies of similar size in the Indian market ($USD38.33K).
Compensation vs Earnings: Mihir's compensation has been consistent with company performance over the past year.
Experienced Management: AAREYDRUGS's management team is considered experienced (2.4 years average tenure).
Experienced Board: AAREYDRUGS's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.6%.
Aarey Drugs & Pharmaceuticals Limited's employee growth, exchange listings and data sources
- Name: Aarey Drugs & Pharmaceuticals Limited
- Ticker: AAREYDRUGS
- Exchange: NSEI
- Founded: 1990
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: ₹821.195m
- Shares outstanding: 25.38m
- Website: https://www.aareydrugs.com
- Aarey Drugs & Pharmaceuticals Limited
- 1227, Hubtown Solaris
- 12th Floor
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/26 00:00|
|End of Day Share Price||2022/06/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.